Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | CASP1 | P29466 | 1/20 | 0.77 |
| ▸ | CASP7 | P55210 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | MAOA | P21397 | 3/20 | 0.73 |
| ▸ | MAOB | P27338 | 3/20 | 0.73 |
| ▸ | MPO | P05164 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31552891 | 1.00 | HPGD (0.77) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| Flavanone SCHEMBL980197 | 0.87 | TP53 (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| Flavanone SCHEMBL29678059 | 0.87 | TP53 (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL2218499 | 0.87 | POLH (0.75) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL31167385 | 0.85 | CYP3A4 (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL157723 | 0.85 | CYP3A4 (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL31741263 | 0.85 | MAPT (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL6242651 | 0.85 | HPGD (0.69) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL311405 | 0.85 | MAPT (1.00) | HPGDMAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL25201659 | 0.84 | KDM4E (0.73) | HPGDMAPTKDM4ESMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012102937-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2012-08-02 | — | — | WO | claimed |
| WO-2005020881-A2 | COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES | SHANGHAI COMMAN PHARMACEUTICAL CO. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | claimed |
| US-9238821-B2 | Metabolic engineering for plant disease resistance | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| WO-2012102937-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2012-08-02 | — | — | WO | disclosed |
| US-20100319084-A1 | METABOLIC ENGINEERING FOR PLANT DISEASE RESISTANCE | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2010-12-16 | — | — | US | disclosed |
| WO-2007038875-A1 | CCR5 RECEPTOR ANTAGONIST MOLECULES | AVANCE PHARMA INC. (CA) | 2007-04-12 | — | — | WO | disclosed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | FNTA, COLGALT1, F3 | HPGD 767/4885MAPT 2106/4885KDM4E 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.